YU65103A - Peg-konjugati hgf-nk4 - Google Patents
Peg-konjugati hgf-nk4Info
- Publication number
- YU65103A YU65103A YU65103A YUP65103A YU65103A YU 65103 A YU65103 A YU 65103A YU 65103 A YU65103 A YU 65103A YU P65103 A YUP65103 A YU P65103A YU 65103 A YU65103 A YU 65103A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- hgf
- conjugates
- peg
- kda
- conjugate
- Prior art date
Links
- 102100021866 Hepatocyte growth factor Human genes 0.000 abstract 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000003827 glycol group Chemical group 0.000 abstract 1
- 210000004898 n-terminal fragment Anatomy 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Konjugat koji se sastoji od N-terminalnog fragmenta faktora rasta hepatocita (HGF/SF) koji sadrži domen ukosnice i α-lanac sa četiri kring regiona i od jedne polietilen glikol grupe sa ukupnom molekulskom težinom od oko 20 do oko 40 kD, pokazuje poboljšana svojstva i može se primeniti kao terapeutski agens u terapiji tumora.[A conjugate comprising an N-terminal fragment of hepatocyte growth factor (HGF/SF) consisting of the hairpin domain and the four kringle regions of the α-chain and a polyethylene glycol group having an overall molecular weight of from about 20 to 40 kDA, has improved properties is a useful therapeutic agent for tumor treatment.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01104640A EP1234583A1 (en) | 2001-02-23 | 2001-02-23 | PEG-conjugates of HGF-NK4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU65103A true YU65103A (sh) | 2006-03-03 |
Family
ID=8176596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU65103A YU65103A (sh) | 2001-02-23 | 2002-02-21 | Peg-konjugati hgf-nk4 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20030012775A1 (sh) |
| EP (2) | EP1234583A1 (sh) |
| JP (2) | JP2004521139A (sh) |
| KR (2) | KR20090020713A (sh) |
| CN (1) | CN100339393C (sh) |
| AR (1) | AR032574A1 (sh) |
| AU (1) | AU2002233354B2 (sh) |
| BG (1) | BG108125A (sh) |
| BR (1) | BR0207510A (sh) |
| CA (1) | CA2438308A1 (sh) |
| CZ (1) | CZ20032511A3 (sh) |
| EC (1) | ECSP034741A (sh) |
| GT (1) | GT200200038A (sh) |
| HR (1) | HRP20030659A2 (sh) |
| HU (1) | HUP0400979A2 (sh) |
| IL (1) | IL157426A0 (sh) |
| MA (1) | MA26998A1 (sh) |
| MX (1) | MXPA03007130A (sh) |
| NO (1) | NO20033737L (sh) |
| PA (1) | PA8540501A1 (sh) |
| PE (1) | PE20020992A1 (sh) |
| PL (1) | PL367402A1 (sh) |
| RU (1) | RU2293574C2 (sh) |
| SK (1) | SK11652003A3 (sh) |
| WO (1) | WO2002074344A2 (sh) |
| YU (1) | YU65103A (sh) |
| ZA (1) | ZA200306080B (sh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003270118A1 (en) * | 2002-08-30 | 2004-03-19 | F. Hoffmann-La Roche Ag | Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma |
| WO2004085471A2 (en) * | 2003-03-24 | 2004-10-07 | Novo Nordisk A/S | Glp-2 derivatives |
| JP2007525981A (ja) | 2004-03-03 | 2007-09-13 | エフ．ホフマン−ラ ロシュ アーゲー | 肝細胞成長因子のｎ末端フラグメントを組み換え発現するための方法 |
| ES2297673T3 (es) * | 2004-03-03 | 2008-05-01 | F. Hoffmann-La Roche Ag | Metodo para la purificacion de un fragmento n-terminal del factor de crecimiento de hepatocitos. |
| US20090202606A1 (en) * | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
| KR101290322B1 (ko) * | 2008-04-09 | 2013-07-26 | 주식회사 바이로메드 | 플라스미드 ｄｎａ의 발현 증강용 동결건조 ｄｎａ 제제 |
| CN102399293B (zh) * | 2008-06-03 | 2013-12-04 | 中国科学院遗传与发育生物学研究所 | 一种与纤维蛋白特异结合的重组蛋白及其应用 |
| US10532020B2 (en) | 2012-08-22 | 2020-01-14 | Revlon Consumer Products Corporation | Nail coatings having enhanced adhesion |
| EP2986306A4 (en) | 2013-04-18 | 2016-12-07 | Armo Biosciences Inc | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING |
| ES2688206T3 (es) | 2013-06-17 | 2018-10-31 | Armo Biosciences, Inc. | Procedimiento de evaluación de la identidad y la estabilidad de proteínas |
| CN105658232A (zh) | 2013-08-30 | 2016-06-08 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
| EP3068425B1 (en) | 2013-11-11 | 2021-01-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| WO2016060996A2 (en) | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| AU2015336101A1 (en) | 2014-10-22 | 2017-04-20 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| CA2986755A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| US10398761B2 (en) | 2015-08-25 | 2019-09-03 | Armo Biosciences, Inc. | Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers |
| JPWO2020158690A1 (ja) * | 2019-01-28 | 2021-12-16 | 東レ株式会社 | 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体 |
| JPWO2020158691A1 (ja) * | 2019-01-28 | 2021-12-02 | 東レ株式会社 | 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2181689T3 (es) | 1992-05-18 | 2003-03-01 | Genentech Inc | Variantes del factor de crecimiento de hepatocitos. |
| US6472178B1 (en) | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
| GB9225448D0 (en) * | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
| CN1229385C (zh) * | 1994-03-31 | 2005-11-30 | 安姆根有限公司 | 刺激巨核细胞生长和分化的组合物及方法 |
| RU2158603C2 (ru) * | 1994-05-31 | 2000-11-10 | Амген Инк. | Способы и препараты для стимулирования роста и дифференцировки мегакариоцитов |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
| EP0816381B1 (en) * | 1995-03-10 | 2004-01-14 | NAKAMURA, Toshikazu | Polyethylene glycol modified hepatocyte growth factor (hgf) |
| DE741187T1 (de) * | 1995-05-05 | 1997-04-30 | Hoffmann La Roche | Rekombinante Obesitäts-(OB)-Proteine |
| US6025324A (en) * | 1996-05-15 | 2000-02-15 | Hoffmann-La Roche Inc. | Pegylated obese (ob) protein compositions |
| CA2277757C (en) | 1997-01-15 | 2008-09-16 | Phoenix Pharmacologics, Inc. | Modified tumor necrosis factor |
| US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| EP0922446A1 (en) * | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
| WO1999055377A2 (en) * | 1998-04-28 | 1999-11-04 | Applied Research Systems Ars Holding N.V. | Polyol-ifn-beta conjugates |
| US6420339B1 (en) * | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| JO2291B1 (en) * | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| CA2431964C (en) * | 2000-12-20 | 2013-09-10 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
-
2001
- 2001-02-23 EP EP01104640A patent/EP1234583A1/en not_active Withdrawn
-
2002
- 2002-02-20 PE PE2002000144A patent/PE20020992A1/es not_active Application Discontinuation
- 2002-02-20 PA PA20028540501A patent/PA8540501A1/es unknown
- 2002-02-21 KR KR1020097002234A patent/KR20090020713A/ko not_active Ceased
- 2002-02-21 RU RU2003127395/15A patent/RU2293574C2/ru not_active IP Right Cessation
- 2002-02-21 WO PCT/EP2002/001837 patent/WO2002074344A2/en not_active Ceased
- 2002-02-21 YU YU65103A patent/YU65103A/sh unknown
- 2002-02-21 US US10/081,309 patent/US20030012775A1/en not_active Abandoned
- 2002-02-21 MX MXPA03007130A patent/MXPA03007130A/es not_active Application Discontinuation
- 2002-02-21 EP EP02700263A patent/EP1389132A2/en not_active Withdrawn
- 2002-02-21 HU HU0400979A patent/HUP0400979A2/hu unknown
- 2002-02-21 HR HR20030659A patent/HRP20030659A2/hr not_active Application Discontinuation
- 2002-02-21 CN CNB028052951A patent/CN100339393C/zh not_active Expired - Fee Related
- 2002-02-21 SK SK1165-2003A patent/SK11652003A3/sk unknown
- 2002-02-21 CA CA002438308A patent/CA2438308A1/en not_active Abandoned
- 2002-02-21 JP JP2002573051A patent/JP2004521139A/ja not_active Withdrawn
- 2002-02-21 PL PL02367402A patent/PL367402A1/xx not_active Application Discontinuation
- 2002-02-21 BR BR0207510-5A patent/BR0207510A/pt not_active IP Right Cessation
- 2002-02-21 KR KR10-2003-7010748A patent/KR20030072629A/ko not_active Ceased
- 2002-02-21 AR ARP020100593A patent/AR032574A1/es not_active Application Discontinuation
- 2002-02-21 IL IL15742602A patent/IL157426A0/xx unknown
- 2002-02-21 CZ CZ20032511A patent/CZ20032511A3/cs unknown
- 2002-02-21 AU AU2002233354A patent/AU2002233354B2/en not_active Ceased
- 2002-02-22 GT GT200200038A patent/GT200200038A/es unknown
-
2003
- 2003-08-06 ZA ZA200306080A patent/ZA200306080B/en unknown
- 2003-08-19 MA MA27285A patent/MA26998A1/fr unknown
- 2003-08-21 EC EC2003004741A patent/ECSP034741A/es unknown
- 2003-08-22 NO NO20033737A patent/NO20033737L/no not_active Application Discontinuation
- 2003-08-22 BG BG108125A patent/BG108125A/bg unknown
-
2007
- 2007-10-10 US US11/869,797 patent/US7846896B2/en not_active Expired - Lifetime
-
2010
- 2010-04-22 JP JP2010099120A patent/JP2010174034A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU65103A (sh) | Peg-konjugati hgf-nk4 | |
| MXPA03006771A (es) | Anticuerpos modificados y metodos de uso. | |
| DE69635026D1 (de) | Varianten des menschlichen wachstumshormons | |
| MX9606386A (es) | Agentes que afectan la hemostasis trombotica. | |
| BR0210056A (pt) | composições e métodos para tratamento de hiperplasia | |
| BR9910251A (pt) | Estimulação hematopoiética | |
| DE60006100D1 (de) | Lang wirkende insulinotrope peptide | |
| DK1028753T3 (da) | Indgivelse af poly(ethylenglycol)-konjugerede molekyler fra nedbrydellige hydrogeler | |
| FR13C0021I2 (fr) | Conjugates d'exendin-4 et leur utilisation medicale | |
| CY1107351T1 (el) | Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης | |
| AU2001235006A1 (en) | Prophylactic and therapeutic monoclonal antibodies | |
| IL146125A0 (en) | Novel quinones as disease therapies | |
| ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
| NO20014085L (no) | Blandinger og fremgangsmåter for forbedring av integritet av kompromitterte kroppspassasjer og hulrom | |
| BG106008A (en) | Novel lhrh antagonists with improved solubility characteristics | |
| AU2001287850A1 (en) | Iron compositions | |
| NO984052D0 (no) | Rekombinante, adenovirale vektorer for human tumorgenterapi | |
| ATE359798T1 (de) | Verwendungvon dextransulfat zur behandlung von ibmir | |
| GB9811465D0 (en) | Glycoproteins having lipid mobilising properties and therapeutic applications thereof | |
| EP0971725A4 (en) | METHOD FOR TREATING SCAR TISSUE | |
| NZ514027A (en) | Cloning and expression of haemophilus somnus transferrin-binding proteins | |
| UY27182A1 (es) | Conjugados peg de hgf-nk4 | |
| UA32281A (uk) | Засіб "регенерин" для зовнішнього лікування гнійних ран і трофічних виразок | |
| TH62376A (th) | Peg คอนจูเกตของ hgf-nk4 |